The drugs considered in this quality metric program include renin–angiotensin system antagonists for hypertension, statins for hypercholesterolemia, and diabetes drugs excluding insulin (i.e., biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, incretin mimetics, meglitinides, or sodium-glucose cotransporter 2 inhibitors). This evidence concerns the gene INS and diabetes mellitus.